You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

~ Buy the JANUMET XR (metformin hydrochloride; sitagliptin phosphate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR JANUMET XR

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for JANUMET XR

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00532935 ↗	MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2008-01-26	A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
NCT00684528 ↗	A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin	Unknown status	Clalit Health Services	Phase 3	2008-06-01	Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00684528 ↗	A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin	Unknown status	Meir Medical Center	Phase 3	2008-06-01	Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00993187 ↗	Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2010-05-04	This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
NCT01065766 ↗	Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)	Completed	Merck Sharp & Dohme Corp.		2009-03-01	This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for JANUMET XR

Condition Name

Chart
Table

Condition Name for JANUMET XR
Intervention	Trials
Type 2 Diabetes Mellitus	6
Diabetes Mellitus, Type 2	6
Bioequivalence	4
Type 2 Diabetes	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for JANUMET XR
Intervention	Trials
Diabetes Mellitus, Type 2	14
Diabetes Mellitus	10
Polycystic Ovary Syndrome	2
Body Weight	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for JANUMET XR

Trials by Country

Map
Table

Trials by Country for JANUMET XR
Location	Trials
United States	9
Canada	5
Mexico	5
Israel	2
Germany	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for JANUMET XR
Location	Trials
Michigan	1
Georgia	1
Texas	1
Florida	1
Colorado	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for JANUMET XR

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for JANUMET XR
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	4
Phase 2	1
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for JANUMET XR
Clinical Trial Phase	Trials
Completed	17
Terminated	1
Unknown status	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for JANUMET XR

Sponsor Name

Chart
Table

Sponsor Name for JANUMET XR
Sponsor	Trials
Merck Sharp & Dohme Corp.	9
Galenicum Health	4
Emory University	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for JANUMET XR
Sponsor	Trials
Industry	16
Other	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.